Severe combined immunodeficiency (SCID) is a group of life-threatening diseases. SCID is caused by mutations that prevent the normal function of the immune system. Infants born with SCID are at very high risk of infectious diseases. One feature of SCID is that T-lymphocytes do not develop normally. In the development of normal T-lymphocytes, the production of circular pieces of DNA called T-lymphocyte receptor excision circles (TRECs) is an important event. It is possible to use the polymerase chain reaction (PCR) to detect TRECs in DNA extracted from a sample of blood. The results of this reaction can be used to identify children with SCID.
- (a)(i)Describe the role of the primers in the PCR used for the detection of TRECs.[3]
- (a)(ii)Suggest and explain how the results of PCR for the detection of TRECs can be used to identify children with SCID.[2]
- (b)(i)Before 2010, children in the United States of America (USA) were tested for SCID either: : if someone in their family history had SCID, or if they developed several infections in a short space of time. From 2010, the USA started to introduce a screening programme for SCID, in which children were tested soon after birth. By 2016, the screening programme was used for nearly all children in the USA. Fig. 2.1 shows the percentage contribution of each of these three approaches to the identification of children with SCID from 2010 to 2016 in the USA. key family history infections screening programme [Figure 2.1] With reference to Fig. 2.1, describe how the contribution of the three approaches to the identification of children with SCID changed from 2010 to 2016.[3]
- (b)(ii)Suggest the advantages of screening all children for SCID soon after birth.[2]
- (c)One form of SCID is caused by a mutation that results in a deficiency of the enzyme adenosine deaminase (ADA). Children with ADA-deficient SCID can be treated with gene therapy using a virus. After successful gene therapy, the children are able to produce ADA for themselves. Suggest how children with ADA-deficient SCID can be treated with gene therapy using a virus.[3]
- (d)Outline the challenges of using a virus for gene therapy.[3]
Mark scheme
Marking points from the official mark scheme (Feb/Mar 2020). The mark or mark type is shown in brackets.
- [3] 2(a)(i) any three from: 1 primer DNA anneals to, single-stranded DNA / denatured DNA ; 2 using complementary base pairing; 3 formation of hydrogen bonds (between primer DNA and TREC DNA); 4 allows, Taq polymerase / DNA polymerase, to bind or starting point for, Taq polymerase / DNA polymerase, to attach; 5 ref. to specificity; e.g. only binds to TREC DNA
- [2] 2(a)(ii) any two from: 1 PCR product means TRECs present/ora ; 2 if PCR detects TRECS, then T-lymphocytes are developing normally / ora; 3 TRECs, do not form / are in small numbers, in children with SCID / ora; 4 (detection of) PCR product means child does not have SCID ;
- [3] 2(b)(i) any three from: 1 contribution (to the identification of children with SCID) by screening programme increased (from 2010 to 2016); 2 contribution (to the identification of children with SCID) by family history decreased and infection decreased (from 2010 to 2016) / AW; 3 between 2012 and 2013 the screening programme became the method with the highest percentage contribution; 4 by 2016 nearly all cases of SCID were diagnosed by the screening programme ; 5 comparative figures to support any of marking points 1 to 4 ; 6 AVP; e.g. some children diagnosed with SCID as a result of infection (despite screening) in 2010 the biggest contribution to diagnosing SCID was through infections
- [2] 2(b)(ii) any two from: 1 early, diagnosis / treatment / AW ; 2 does not rely on family knowing about family history of SCID ; 3 prevents child with SCID from developing several infections before diagnosis ; 4 removes worry if not present ;
- [3] 2(c) any three from: 1 isolate / obtain, functional / normal, ADA allele ; A gene throughout 2 insert allele into virus (vector) ; I ref. to plasmid 3 remove, stem cells / T-lymphocytes / target cells ; 4 insert, allele / gene / virus, into, stem cells / T-lymphocytes / target cells ; 5 return, stem cells / T-lymphocytes / target cells, to body; 6 AVP; e.g. ref. to retrovirus / lentivirus ref. to difficulty in finding suitable donor for bone marrow transplant
- [3] 2(d) any three from: 1 (retrovirus / lentivirus) can insert, viral DNA / healthy allele, randomly into (host) DNA ; 2 may cause, cancer / side effects / allergic response ; 3 inserted, allele / DNA, may be inactivated or inserted, allele / DNA, may inactivate another (host) gene ; 4 virus may not enter, target cells / T-lymphocytes or virus may enter non-target cells; 5 AVP; e.g. ref. to safe / clean, conditions required to produce virus ineffective immune response against virus
Write your answer and get it marked
On Oracle Prep you can write or photograph your own answer and have it marked by AI against this mark scheme, with feedback on what you missed.
Sign up free →